STAT and Undark Investigation Puts BPC-157's Evidence Base Under Scrutiny Weeks Before the July PCAC Vote
A STAT and Undark investigation, supported by the Pulitzer Center and widely republished around June 1-2, examined the thin evidence behind BPC-157, the wound-healing peptide on the FDA's July 23-24 PCAC docket. Nearly all of the roughly 200 BPC-157 studies indexed on PubMed list Croatian researcher Predrag Sikiric or colleague Sven Seiwerth as an author, a concentration a Polish review team flagged as a confirmation-bias risk, and Sikiric's undisclosed conflicts include patents dating to 1989 and a CEO role at Diagen, which sells a patented version. Only three human studies have been published; STAT ran a June 1 follow-up carrying Sikiric's response to skeptics.